Bergenbio ASA (BGBIO) - Total Assets
Based on the latest financial reports, Bergenbio ASA (BGBIO) holds total assets worth Nkr86.75 Million NOK (≈ $9.13 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BGBIO equity to assets ratio to measure how much of total assets are equity-financed.
Bergenbio ASA - Total Assets Trend (2013–2024)
This chart illustrates how Bergenbio ASA's total assets have evolved over time, based on quarterly financial data. Check Bergenbio ASA tangible book value ratio to evaluate the tangible quality of the company's equity base.
Bergenbio ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Bergenbio ASA's total assets of Nkr86.75 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr140.16 Million | 90.0% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr1.25 Million | 0.8% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Bergenbio ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bergenbio ASA stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bergenbio ASA's current assets represent 99.2% of total assets in 2024, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 90.0% of total assets in 2024, up from 68.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is cash and equivalents at 90.0% of total assets.
Bergenbio ASA Competitors by Total Assets
Key competitors of Bergenbio ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Bergenbio ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.39 | 5.05 | 14.94 |
| Quick Ratio | 4.39 | 5.05 | 14.94 |
| Cash Ratio | 0.00 | 4.63 | 0.00 |
| Working Capital | Nkr66.93 Million | Nkr175.04 Million | Nkr787.34 Million |
Bergenbio ASA - Advanced Valuation Insights
This section examines the relationship between Bergenbio ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.69 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | Nkr155.80 Million |
| Market Capitalization | $7.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bergenbio ASA's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bergenbio ASA's assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bergenbio ASA (2013–2024)
The table below shows the annual total assets of Bergenbio ASA from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr155.80 Million ≈ $16.39 Million |
-10.63% |
| 2023-12-31 | Nkr174.34 Million ≈ $18.35 Million |
+4.58% |
| 2022-12-31 | Nkr166.71 Million ≈ $17.54 Million |
-62.97% |
| 2021-12-31 | Nkr450.24 Million ≈ $47.38 Million |
-39.01% |
| 2020-12-31 | Nkr738.20 Million ≈ $77.68 Million |
+173.03% |
| 2019-12-31 | Nkr270.38 Million ≈ $28.45 Million |
-28.63% |
| 2018-12-31 | Nkr378.83 Million ≈ $39.86 Million |
-1.43% |
| 2017-12-31 | Nkr384.34 Million ≈ $40.44 Million |
+120.21% |
| 2016-12-31 | Nkr174.54 Million ≈ $18.37 Million |
+111.84% |
| 2015-12-31 | Nkr82.39 Million ≈ $8.67 Million |
-39.37% |
| 2014-12-31 | Nkr135.89 Million ≈ $14.30 Million |
+662.97% |
| 2013-12-31 | Nkr17.81 Million ≈ $1.87 Million |
-- |
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.